Japan Opioid Induced Constipation (OIC) Treatment Market Hits US$93.2 Million in 2025, PAMORAs Lead Demand - Outlook to 2034 | DataM Intelligence

TOKYO, Japan and Leander, Texas - Nov. 24. 2025

The Japan Opioid Induced Constipation (OIC) Treatment Market was valued at approximately US$ 93.2 million in 2025 and is projected to reach around US$ 192-200 million by 2034, expanding at a CAGR of about 7.5% during the forecast period 2025-2034.

The Global Opioid Induced Constipation Treatment Market reached US$ 1,126.13 million in 2023 and is expected to reach US$ 1,641.20 million by 2031, growing at a CAGR of 5.0% during the forecast period 2024-2031.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/opioid-induced-constipation-treatment-market?praveen

Recent Industry Developments - Japan

🔹August 2025 - Rise in prescription of next-generation PAMORAs
Japan reports growing adoption of advanced PAMORA drugs supported by strong real-world data on improved bowel function and reduced opioid discontinuation rates. This trend is reshaping chronic pain management strategies nationwide.

🔹June 2025 - Smart gastrointestinal monitoring tools gain rapid uptake
Japanese clinics are integrating automated motility tracking devices and predictive-risk algorithms to detect early OIC symptoms. This enhances proactive care workflows and reduces dependence on emergency gastrointestinal procedures.

🔹April 2025 - R&D in gut-targeted regenerative therapies accelerates
Japan's leadership in gut microbiome and neuroenteric research is fueling innovation in regenerative and microbiota-modulating solutions for long-term OIC management. Clinical trials are progressing toward commercial readiness backed by strong institutional investments.

Recent Industry Developments - United states

🔹October 2025 - Surge in peripherally acting μ-opioid receptor antagonists (PAMORAs) adoption U.S. hospitals and pain-management centers are increasingly shifting toward high-efficacy PAMORAs such as naloxegol and naldemedine to reduce opioid-related gastrointestinal complications. The move aims to improve adherence to chronic pain therapy while reducing emergency visits linked to severe constipation.

🔹September 2025 - AI-driven opioid monitoring expands across clinical systems
Healthcare networks in the U.S. are integrating AI-enabled patient monitoring platforms to track opioid dosage, bowel movement patterns, and early signs of OIC. This digital intervention is decreasing late-stage complications and optimizing personalized OIC treatment planning.

🔹 June 2025 - Novel combination therapies gain regulatory momentum
The FDA has granted accelerated pathways for new OIC combination regimens that pair opioid analgesics with gastrointestinal motility enhancers. These therapies aim to maintain pain control while minimizing constipation, improving overall patient quality of life and long-term opioid tolerance.

(OIC) Market: Key Drivers

The OIC treatment market is expanding rapidly as global opioid usage rises for chronic pain, cancer pain, and post-surgical management. OIC affects up to 60-80% of opioid users, making it one of the most common and burdensome side effects.

Advancements in PAMORAs, stool softeners, osmotic laxatives, combination therapies, and AI-guided medication monitoring are significantly improving treatment outcomes. Increasing awareness among clinicians, growing patient preference for minimally invasive and non-disruptive treatments, and a robust drug development pipeline are accelerating market growth.

Lifestyle and clinical risk factors such as dehydration, dietary habits, aging populations, and long-term opioid dependence further increase OIC prevalence. Expanding access to specialized pain clinics, government opioid-safety programs, and improved reimbursement for advanced therapeutics support strong market momentum.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/opioid-induced-constipation-treatment-market?praveen

(OIC) Market: Major Players

1.Shionogi & Company, Limited
Shionogi is a notable participant in the OIC treatment landscape, supported by its strong portfolio in pain management and gastrointestinal therapeutics. The company's ongoing R&D investments and strategic collaborations in opioid-related side-effect management position it as a growing contributor to the global OIC market. While specific market-share disclosures are limited, Shionogi continues expanding its influence through innovation-driven drug development.

2.Takeda Pharmaceutical Company Ltd.
Takeda remains one of the most prominent players in the OIC treatment market, driven by its globally recognized PAMORA therapy Movantik (naloxegol). Strong clinical performance, widespread prescription across pain-management centers, and sustained commercial momentum reinforce Takeda's leadership. The company's strategic focus on gastrointestinal and pain-related conditions further strengthens its standing in the OIC treatment space.

Segment Covered in the (OIC) Market:

A ) By Distribution Channel

1. Hospital Pharmacies
Hospital pharmacies account for a major share of OIC drug distribution, especially for cancer patients and individuals receiving inpatient opioid therapy. The availability of PAMORAs, prescription laxatives, and combination therapies within hospital settings ensures rapid treatment initiation and close clinical monitoring.

2. Retail Pharmacies
Retail pharmacies serve as a key access point for outpatient chronic pain patients. High OTC availability of laxatives and strong prescription volume for OIC therapies contribute to steady market growth in this segment.

3.Online Pharmacies
The online channel is expanding rapidly due to rising digital health adoption, home delivery preferences, and increased chronic opioid use in remote or aging populations. Competitive pricing and easy access to long-term OIC medications support strong momentum.

B ) By Route of Administration

1) .Oral Route

Oral formulations including PAMORA tablets, osmotic laxatives, and stool softeners dominate the market due to convenience, patient compliance, and suitability for long-term use. Most chronic non-cancer pain patients prefer oral therapies for daily management.

2.Parenteral Route (Injectable)
Injectable formulations, such as methylnaltrexone injections, are primarily used in severe cases or when rapid onset is required especially in hospitalized, cancer, or palliative-care patients. This segment holds a smaller but critical share for immediate OIC intervention.

Regional Analysis

1) North America
Holds around 45-48% of the global OIC treatment market. High opioid utilization rates, strong adoption of PAMORAs, advanced pain clinics, and favorable reimbursement support regional leadership.

2) Europe
Accounts for approximately 22-25% of the market. Universal healthcare systems and rising focus on opioid-safety guidelines drive stable growth.

3) Asia-Pacific
Represents about 18-20%, emerging as the fastest-growing region due to rising cancer cases, improved pain-care access, and adoption of advanced gastrointestinal therapeutics.

4) Latin America
Holds 5-6% share, with Brazil and Mexico driving demand as opioid prescribing and chronic pain awareness expand.

5) Middle East & Africa
Together account for 4-5%, reflecting early-stage but expanding OIC treatment adoption due to modernization of healthcare and increasing cancer-related opioid usage.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=opioid-induced-constipation-treatment-market?praveen
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.